Navigation Links
Timothy I. Still Appointed CEO at Accumetrics
Date:10/30/2008

SAN DIEGO, Oct. 30 /PRNewswire/ -- Accumetrics, Inc. has appointed Timothy I. Still to the additional position of Chief Executive Officer. Mr. Still has been serving in the capacity of President and Chief Operating Officer for the company since earlier this year.

"Tim has the right combination of industry, management, and startup experience for our Board," says Tony Arnerich, General Partner of Arnerich & Massena and Executive Chairman of the Board at Accumetrics. "His commercialization expertise and diagnostic market experience will be invaluable as we build key partnerships and move forward with the commercialization of our technology."

Mr. Still's background includes over 18 years of sales, marketing and business development experience in healthcare and medical diagnostics. He has extensive experience in designing and implementing highly focused sales and marketing strategies within both large and small companies.

Prior to Accumetrics, Mr. Still was Executive Vice President and Chief Commercial Officer for HemoSense, a medical diagnostic company located in San Jose, California. He was instrumental in building HemoSense into a rapidly growing, publicly traded company which was acquired by Inverness Medical in November 2007.

Before joining HemoSense, Mr. Still served as Vice President of Sales and Marketing for Cholestech Corporation, and served in a variety of sales, marketing and business development roles for Boehringer Mannheim Corporation (now Roche Diagnostics).

Mr. Still received a B.S. degree (with Honors) in Biological Sciences from the University of California at Davis, and an MBA (Deans Scholar) in Marketing and Entrepreneurship from the University of Southern California.

About Accumetrics (http://www.accumetrics.com):

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

VerifyNow is the first simple and rapid system for measuring the individual response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow system provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.

CONTACT: Jules Abraham

Lippert Heilshorn & Associates

212-838-3777

jabraham@lhai.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HeartWare Appoints Timothy J. Barberich to Board of Directors
2. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
3. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
4. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
5. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
6. Excalibur - Transforming Biotech Deals can Still be Achieved
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. Still River Systems Announces Operation of the Worlds Highest Magnetic Field Cyclotron
9. Federal nanotech risk research plan still comes up short
10. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
11. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):